US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
NICE backs ‘pioneering’ treatment for advanced breast cancer
Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment. Find out more.
Improving Treatment Access to Innovative Therapies in Breast Cancer
Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.
SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer
Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.
Innovations in Breast Cancer Treatment With Dr Dawn Klemow
Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
AdventHealth in Palm Coast adds advanced cancer treatment center to its Flagler campus
The $30 million facility was made possible, in part, through a $4 million contribution through the AdventHealth Palm Coast ...
PharmiWeb16h
Global Cancer Therapeutics Market Forecast 2024-2032: Key Trends, Growth Drivers, and a Projected Expansion to USD 437.3 Billion
IntroductionThe global cancer therapeutics market is on an exponential growth trajectory, driven by advancements in treatment ...
Rolling Out8d
3 crucial breast cancer warning signs Black women must know
Discover the 3 critical warning signs of breast cancer that every Black woman should know, plus insights on early detection ...
BlackDoctor2d
How Heart Disease Increases Breast Cancer Risk for Black Women
Heart disease and breast cancer are two of the most significant health threats facing Black women today. Here's ...
CytoMed, a Singapore Biotech, Revolutionizes Cancer Treatment Using Donor Immune Cells
Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...
Oncology Nurse Advisor3d
Breast Cancer Screening Guidelines Changes in 2009 Led to Decline in In Situ Rates
Researchers sought to determine the effect of changes in screening guidelines on incidence of breast cancer by stage at diagnosis and surgical management.